BBIO - Conference and earnings call announcements

PALO ALTO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in fireside chats at the following healthcare investor conferences: BofA Securities Health Care Conference 2026, Las Vegas, NV: Tuesday, May 12 at 2:20 pm PDT2026 Jefferies Global Healthcare Conference, New York, NY: Thursday, June 4 at 11:05 am EDTGoldman Sachs 47th Annual Global Healthcare Conference, Miami FL: Tuesday, June 9 at 8:00 am EDT To access the live webcast of BridgeBio's presentations, please visit the "E

PALO ALTO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in the following healthcare investor conferences: TD Cowen 46th Annual Healthcare Conference, Boston, MA: Fireside Chat on Monday, March 2 at 3:50 pm ESTLeerink Partners Global Healthcare Conference, Miami, FL: Fireside Chat on Tuesday, March 10 at 1:00 pm EDTBarclays 28th Annual Global Healthcare Conference, Miami FL: Fireside Chat on Wednesday, March 11 at 12:30 pm EDT To access the live webcast of BridgeBio's prese

PALO ALTO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that co-founder and CEO, Neil Kumar, Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 12 at 7:30 am PT. To access the live webcast of BridgeBio's investor webinar, please visit the "Events & Presentations" page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 30 days following the event. About BridgeBio Pharma

PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Friday, January 9, 2026 at 8:00 am ET with Janet Legare, M.D., Professor in the Divisions of Genetics and Metabolism and Developmental Pediatrics and Rehabilitation Medicine in the Department of Pediatrics at the University of Wisconsin (UW) School of Medicine and Public Health and investigator in PROPEL 3, the registrational Phase 3 study of infigratinib for children with achondroplasia. Dr. Legare also serves as director of both the Midwest

PALO ALTO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will participate in fireside chats at the following healthcare investor conferences: Piper Sandler Healthcare Conference, New York, NY: Fireside Chat on Tuesday, December 2 at 10:30 am ESTEvercoreISI HealthCONx Conference, Miami, FL: Fireside Chat on Wednesday, December 3 at 3:00 pm EST To access the live webcast of BridgeBio's presentations, please visit the "Events and Presentations" page within the Investors section of the BridgeBio website at ht

PALO ALTO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host fireside chats at the following healthcare investor conferences: UBS Global Healthcare Conference, Palm Beach Gardens, FL: Fireside Chat on Monday, November 10 at 1:15 pm ESTJefferies Global Healthcare Conference, London, UK: Fireside Chat on Tuesday, November 18 at 11:00 am EST To access the live webcast of BridgeBio's presentations, please visit the "Events and Presentations" page within the Investors section of the BridgeBio website at

PALO ALTO, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host two separate business update calls to share the following: Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) FORTIFY Phase 3 Interim Analysis Topline Results Webinar: Monday, October 27 at 8:00 am ETQ3 2025 Earnings: Wednesday, October 29 at 4:30 pm ET To access the live webcast for BridgeBio's calls, please visit the "Events and Presentations" page within the Investors section of the BridgeBio website at https://investor.bridgebio.com

PALO ALTO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Wednesday, September 10, 2025 at 8:00 am ET with Rachel Gafni, M.D., Senior Research Physician at the National Institute of Dental and Craniofacial Research, part of the National Institutes of Health (NIH) and Principal Investigator and Steering Committee Co-Chair for CALIBRATE, the Company's Phase 3 clinical trial for autosomal dominant hypocalcemia type 1 (ADH1). Dr. Gafni will provide an overview of ADH1, specifically focusing on pathoph

PALO ALTO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host fireside chats at the following healthcare investor conferences: Wells Fargo Healthcare Conference, Boston, MA: Fireside chat on Wednesday, September 3 at 9:30 am ETCantor Global Healthcare Conference – New York, NY: Fireside chat on Thursday, September 4 at 2:10 pm ETMorgan Stanley Global Healthcare Conference – New York, NY: Fireside chat on Monday, September 8 at 3:20 pm ET To access the live webcast of BridgeBio's presentations, please

PALO ALTO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Friday, July 11, 2025 at 8:00 am ET with Matthew Wicklund, M.D., FAAN, Professor of Neurology and Vice Chair for Research, Department of Neurology at the University of Texas (UT) Health Science Center San Antonio. Dr. Wicklund will provide an overview of limb-girdle muscular dystrophy (LGMD), specifically focusing on the disease burden, standard of care and unmet needs for those with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) (FKR

PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami, FL on Monday, June 9 at 8:40 am ET. To access the live webcast of BridgeBio's presentation during the fireside chat, please visit the "Events & Presentations" page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 30 days follow

PALO ALTO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will participate in a fireside chat at the Bank of America Merrill Lynch Global Healthcare Conference 2025 in Las Vegas, NV on Wednesday, May 14 at 2:20 pm PT. To access the live webcast of BridgeBio's presentation, please visit the "Events" page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 30 days following the event. About BridgeBio Pha

PALO ALTO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that co-founder and CEO, Neil Kumar, Ph.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13 at 7:30 am PT. To access the live webcast of BridgeBio's presentation, please visit the "Events & Presentations" page within the Investors section of the BridgeBio website at https://investor.bridgebio.com/news-and-events/event-calendar. A replay of the webcast will be available on the BridgeBio website for 30 days following the event.

PALO ALTO, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that members of the management team will participate in the following upcoming investor conferences: Morgan Stanley 22nd Annual Global Health Care Conference, New York, NY: Fireside Conversation on September 4th at 10:00 am ETWells Fargo 19th Annual Healthcare Conference 2024, Boston, MA, September 5thCantor Global Healthcare Conference, New York, NY: Presentation on September 17th at 10:20 am ET To access the live webcast of BridgeBio's presentations, please visit the "Events" page within the Inve

PALO ALTO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that Neil Kumar, Ph.D., founder and CEO of BridgeBio, will present at the Goldman Sachs Annual Global Healthcare Conference in Miami, FL on Wednesday, June 12 at 3:20 pm EDT. To access the live webcast of BridgeBio's presentation, please visit the "Events & Presentations" page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 90 days following the event.  About

PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at the Bank of America Merrill Lynch Global Healthcare Conference 2024 in Las Vegas, NV on Wednesday, May 15 at 3:00 pm PT. To access the live webcast of BridgeBio's presentation, please visit the "Events & Presentations" page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 90 days following the event. About Bri

PALO ALTO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 8 at 8:15 am PT. To access the live webcast of BridgeBio's presentation, please visit the "Events & Presentations" page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 30 days following the event. About BridgeBio Pharma

PALO ALTO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at the Morgan Stanley 21st Annual Global Healthcare Conference in New York, NY on Tuesday, September 12 at 10:50 am ET. To access the live webcast of BridgeBio's presentation, please visit the "Events & Presentations" page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 90 days following the event. About Bridg

PALO ALTO, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at the Bank of America Merrill Lynch Global Healthcare Conference in Las Vegas, NV on Wednesday, May 10 at 10:00 am PT. To access the live webcast of BridgeBio's presentation, please visit the "Events & Presentations" page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 90 days following the event. About Bridg

PALO ALTO, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in the following upcoming investor conferences: SVB Securities Global Biopharma Conference, Virtual: Tuesday, February 14th at 2:20 pm ETGoldman Sachs Bus Tour, San Francisco, CA: Wednesday, March 1st at 8:00 am PTCowen 43rd Annual Healthcare Conference, Boston, MA: Wednesday, March 8th at 10:30 am ET To access the live webcast of BridgeBio's fireside chats at the SVB Securities Global Biopharma Conference and the C

PALO ALTO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 9 at 3:00 pm PT. To access the live webcast of BridgeBio's presentation, please visit the "Events & Presentations" page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 90 days following the event. About BridgeBio Pharma

PALO ALTO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in the following upcoming investor conferences:  Jefferies Health Care Conference, London, UK: November 15th at 9:40 am ETEvercore ISI HealthCONx Conference, Virtual: November 30th at 10:05 am ET  To access the live webcast of BridgeBio's presentations, please visit the "Events" page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcasts will be available on

PALO ALTO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in the following upcoming investor conferences:  Citi's 17th Annual BioPharma Conference, Boston, MA: September 7th at 8:50 am ET Morgan Stanley Global Healthcare Conference, New York, NY: September 13th at 7:20 am ET Baird Global Healthcare Conference, New York, NY: September 14th at 12:50 pm ET H.C. Wainwright 24th Annual Global Investment Conference, New York, NY: September 14th at 11:30 am ETCantor Fitzgerald's

PALO ALTO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in the following upcoming investor conferences: Jefferies Healthcare Conference, New York, NY: Thursday, June 9th at 4:00 pm ETGoldman Sachs Global Healthcare Conference, Ranchos Palos Verdes, CA: Wednesday, June 15th at 5:00 pm ET To access the live webcast of BridgeBio's presentations, please visit the "Events" page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of

PALO ALTO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in the following upcoming investor conferences: Citi Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Panel, Virtual: Wednesday, May 18th at 2:30 pm ETH. C. Wainwright Global Investment Conference, Virtual: Tuesday, May 24th at 7:00 am ETUBS Global Healthcare Conference, New York, NY: Tuesday, May 24th at 11:30 am ETJ. P. Morgan West Coast Investor Day, San Francisco, CA: Tuesday, May 24th at 12:00 pm ET To access more

PALO ALTO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will participate in the Bank of America Securities Healthcare Conference in Las Vegas, NV on Wednesday, May 11th at 7:40 pm ET. To access the live webcast of BridgeBio's presentation, please visit the "Events & Presentations" page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 90 days following the event. About BridgeBio Ph